Tivicay
NDC Package 53002-1810-6
Package Information
Tivicay is and TIVICAY PD are indicated in combination with other antiretroviral agents for the treatment of HIV‑1 infection in adults (treatment-naïve or -experienced) and in pediatric patients (treatment-naïve or -experienced but integrase strand transfer inhibitor [INSTI]-naïve) aged at least 4 weeks and weighing at least 3 kg [see Microbiology (12.4)].TIVICAY is indicated in combination with rilpivirine as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure or known substitutions associated with resistance to either antiretroviral agent. Marketed by Rpk Pharmaceuticals, Inc., this product is identified by NDC 53002-1810 and is authorized under FDA application NDA204790.
Identification & Billing
- RxCUI: 1433873 - dolutegravir 50 MG Oral Tablet
- RxCUI: 1433873 - dolutegravir 50 MG (as dolutegravir sodium 52.6 MG) Oral Tablet
- RxCUI: 1433879 - Tivicay 50 MG Oral Tablet
- RxCUI: 1433879 - dolutegravir 50 MG Oral Tablet [Tivicay]
- RxCUI: 1433879 - Tivicay 50 MG (as dolutegravir sodium) Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 53002 - Rpk Pharmaceuticals, Inc.
- 53002-1810 - Tivicay
- 53002-1810-6 - 6 TABLET, FILM COATED in 1 BOTTLE
- 53002-1810 - Tivicay
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 53002-1810-6 identifies a specific commercial package of 6 tablet, film coated in 1 bottle of Tivicay, labeled by Rpk Pharmaceuticals, Inc.. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Rpk Pharmaceuticals, Inc. on August 13, 2013. The current certification is valid through December 31, 2024.
How is this Rpk Pharmaceuticals, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 53002181006. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.